Clinical aspects of natural anti-angiogenic drugs.
Natural products represent a rich resource for drug delivery and are currently being exploited to target tumour angiogenesis. A vast array of products of natural origin have been shown to have anti-angiogenic potential in preclinical models, including purified endogenous inhibitors, and exogenous compounds derived from varied species of plant, animal and micro-organism. Over a dozen of these agents have now entered clinical trial. This review discusses evidence for the efficacy of this drug class and key issues in the translation of pre-clinical results into the development of efficacious drugs for clinical use.
Cancer Biomarkers and Prevention Group, Biocentre, University of Leicester, Leicester, UK.
C P
CP
Neal
D P
DP
Berry
H
H
Doucas
M M
MM
Manson
W
W
Steward
G
G
Garcea
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D020533:Angiogenesis Inhibitors; D001688:Biological Products